Document ID: chunk:federal_register_of_legislation:F2024C01214:reg:2:p3
Version: federal_register_of_legislation:F2024C01214
Segment Type: reg
Provision Reference: reg 2 (pt 3/4)
Character Range: 34618–37500

and other maintenance is to be carried out by Abbott, or another person approved by it, at least once every 12 months
                  * any necessary repairs are to be undertaken by Abbott or another person approved by it.
 Operating     In a manner not inconsistent with the manufacturer's instructions for operating the device, provided that:
                  * compliance with any action recommended in those instructions is to be regarded as mandatory
                  * Alere DDS-2 or Abbott SoToxaTM Test Kit is to be used
                * each test result is to be printed out.

Schedule 5 Method — determining sample identifiers to be allocated to body samples

1 Method
       The method for determining sample identifiers to be allocated to body samples that approved testers take under Subpart 99.C of CASR and send for confirmatory drug tests, is specified in this Schedule.

2 Provision of sample identification numbers by approving authority
       CASA, or a person authorised in writing by CASA (the approving authority), must, from time to time, approve a group of sequences of sample identification numbers for each approved tester to use in accordance with this Schedule.

3 Provision of further sample identification numbers by approving authority
       The approving authority must ensure that sufficient approved groups of sequences of sample identification numbers are available to ensure that each approved tester is assigned sufficient numbers to enable the approved tester to allocate a number to a body sample in accordance with clause 5 or 6.

4 Assignment of sample identification numbers to approved testers
      (1) The approving authority must, from time to time, assign to an approved tester sample identification numbers from the group of sequences approved and in the order in which they were so approved.
      (2) The approving authority must assign sufficient numbers to enable the approved tester to cover the number of confirmatory tests that may arise from the volume of initial drug tests anticipated to be undertaken by the approved tester during a period agreed between the approving authority and the approved tester.
      (3) No sequence of numbers assigned by an approving authority to an approved tester may later be assigned by the approving authority to any other approved tester.
      (4) The approving authority must maintain a record of each sequence of numbers assigned by it, and of the approved tester to whom it is assigned, and make that record available to CASA on request.

5 Allocation of sample identification numbers by approved tester
      (1) When an approved tester conducts an initial drug test for which a positive result is recorded, the approved tester is to allocate to the body sample that is to be sent for a confirmatory drug test a sample identification number chosen from, and in the order